{
  "nctrialId": "HC-1758",
  "title": "A Randomized Double-Blind, Placebo-Controlled  Study of LUP-223 (calcineurin inhibitor) in Patients With Psoriasis",
  "officialTitle": "A Randomized Double-Blind, Placebo-Controlled  Study of LUP-223 (calcineurin inhibitor) in Patients With Psoriasis",
  "sponsor": "Canadian Blood Services",
  "indication": "Psoriasis",
  "phase": "Phase 1/Phase 2",
  "fileName": "HC-1758.json",
  "fileSize": 247294,
  "date": "2023-07-25",
  "completionDate": "2027-07-20",
  "drugName": "LUP-223 (calcineurin inhibitor)",
  "source": "Health Canada Clinical Trials Database",
  "studyType": "Interventional",
  "status": "Active, not recruiting",
  "description": "This is a randomized double-blind, placebo-controlled  study designed to evaluate the efficacy and safety of LUP-223 (calcineurin inhibitor) in patients with Psoriasis. The study will enroll approximately 353 patients.",
  "eligibilityCriteria": "\nInclusion Criteria:\n- Adults aged 25-65 years\n- Confirmed diagnosis of Psoriasis\n- ECOG performance status 0-1\n- Adequate organ function\n- Willing and able to provide informed consent\n\nExclusion Criteria:\n- Known hypersensitivity to study drug or excipients\n- Pregnant or breastfeeding women\n- Participation in another interventional study within 30 days\n- Significant cardiovascular disease within past 6 months\n- Active or chronic infection requiring systemic treatment"
}